Deanne Mraz Robinson, MD
About
Biography
Deanne Mraz Robinson, MD, FAAD, is a fellowship-trained, board-certified dermatologist based in CT. A leader in the field, she is the Chief Medical Officer of Ideal Image, the nation’s largest aesthetic provider. She is also President and Co-Founder of Modern Dermatology of Connecticut. As an authoritative voice in aesthetics, she is intimately involved with clinical research, speaking, and teaching.
Appointments
Dermatology
Assistant Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- MD
- Univ of Rochester School of Medicine & Dentistry (2008)
Research
Publications
2023
Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Robison T, Widgerow A. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 23: 1266-1270. PMID: 38206144, DOI: 10.36849/jdd.7622.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsFacial dyschromiaMulti-center trialClinical studiesBlinded clinical studyTopical productsALS cohortExtension studyHydroquinone 4%Follow-up visitExtension phaseClearance of pigmentAssociated with increased productionMulti-centerDaily sunscreen useReduced clearanceCohortDyschromiaSunscreen useIn vitroWeeksTrialsLong-term basisSignificant reboundSkinEfficacyA Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Widgerow A. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 22: 333-338. PMID: 37026875, DOI: 10.36849/jdd.7340.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsModified Melasma Area Severity IndexHydroquinone 4%Post-inflammatory hyperpigmentationFacial dyschromiaBlinded clinical studyFollow-upClinical studiesTopical productsAdverse eventsModified melasma area severity index scoreMulti-centerMelasma Area Severity IndexArea Severity IndexNo adverse eventsClearance of pigmentIn vitro studiesExcessive sun exposureBlinded investigatorRight cheekWeek 4Griffiths ScalesReduced clearanceSun exposureMedical disordersTolerability assessments
2022
Advances in Pigmentation Management: A Multipronged Approach.
Widgerow A, Wang J, Ziegler M, Fabi S, Garruto J, Robinson D, Bell M. Advances in Pigmentation Management: A Multipronged Approach. Journal Of Drugs In Dermatology 2022, 21: 1206-1220. PMID: 36342738, DOI: 10.36849/jdd.7013.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsGene expression profilesCell linesExpression profilesProduction of pigmentsGene expression studiesMultiple cell linesProduction of melaninAffecting pigmentationPigment productionCellular pathwaysExpression studiesEndothelial cellsSynthesize melaninDistribute melaninMelanocyte linesIndependent pathwaysInhibitor of melanogenesisHuman skin pigmentationNeighboring keratinocytesCell typesHexapeptide-11Inflammation-related factorsGenesPathwayEndothelial cell interactions